The speed at which a person biologically ages may be partially written in the bacteria living in their gut — a connection with real implications for how longevity researchers think about modifiable aging levers. While epigenetic clocks have matured into reliable biomarkers of biological age, identifying upstream drivers of aging pace has remained elusive. This study offers a rare pairing of gut microbiome profiling with a dynamic methylation-based aging metric, producing testable bacterial targets.
The research analyzed 123 monocyte-enriched samples from a cohort that included Native Hawaiian and Pacific Islander participants — a population rarely represented in aging genomics. Using 16S rRNA gene sequencing alongside DNA methylation data, investigators trained machine learning models (branded "EpiBiome") to predict DunedinPACE, a clock designed to measure the instantaneous pace of biological aging rather than a static age estimate. Crucially, static epigenetic clocks — Horvath, Levine, and GrimAge2 — showed no predictive signal from gut bacteria. Only DunedinPACE responded, with species-level models explaining roughly 15% of variance (R² = 0.152, permutation p < 0.001). SHAP analysis flagged Bifidobacterium adolescentis as the top contributor to decelerated aging pace, while Succinivibrio dextrinosolvens was most strongly associated with acceleration.
This distinction between dynamic and static clocks is scientifically significant: DunedinPACE captures aging momentum, not just accumulated damage, making it arguably more sensitive to current biological exposures like diet and microbiome state. The Bifidobacterium finding aligns with an existing body of literature linking this genus to anti-inflammatory activity, gut barrier integrity, and longevity-associated metabolite production — lending the result biological plausibility. However, the study's limitations are substantial. With only 123 samples, the models risk overfitting despite permutation testing. The cohort is not broadly generalizable, the cross-sectional design precludes causal inference, and monocyte-enriched rather than whole-blood methylation introduces tissue-specificity questions. This is a hypothesis-generating proof-of-concept — valuable for directing future intervention studies — but far from establishing that altering gut flora measurably slows biological aging pace.
